STAT3 ACTIVATION AS A MARKER FOR CLASSIFICATION AND PROGNOSIS OF DLBCL PATIENTS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 6, 2014
app pub date -
Nov 28, 2012
filing date -
Nov 29, 2011
priority date (Note) -
Published
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
Methods are disclosed for determining classification and prognosis of patients with diffuse large B-cell lymphoma (DLBCL) using activation of signal transducer and activator of transcription 3 (STAT3).
Loading the Abstract Image...
OK
First Claim
Family
Loading Family data...
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully